sellWeak cluster of 510b5-1 plan
Catriona Yale sold $3.0M of AKRO
Chief Development Officer at Akero Therapeutics, Inc.. 53,590 shares at an average of $56.25, traded Jan 27, 2025, filed Jan 31, 2025.
Warning score
30Value
$3.0M
53,590 shares
Holdings after
95,648
-36% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$3.0M at market
- +10Share of holdings soldSold 36% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-011445, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 27, 2025 | MOption exercise Common Stock10b5-1 | +16,849 | $0.62 | $10k | 112,497 | Jan 31, 2025 |
| Jan 27, 2025 | MOption exercise Common Stock10b5-1 | +15,172 | $6.36 | $97k | 127,669 | Jan 31, 2025 |
| Jan 27, 2025 | MOption exercise Common Stock10b5-1 | +21,569 | $21.09 | $455k | 149,238 | Jan 31, 2025 |
| Jan 27, 2025 | SOpen-market sale Common Stock10b5-1 | -17,000 | $55.16 | $938k | 132,238 | Jan 31, 2025 |
| Jan 27, 2025 | SOpen-market sale Common Stock10b5-1 | -9,250 | $55.95 | $518k | 122,988 | Jan 31, 2025 |
| Jan 27, 2025 | SOpen-market sale Common Stock10b5-1 | -27,340 | $57.02 | $1.6M | 95,648 | Jan 31, 2025 |
| Jan 27, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,849 | $0.00 | $0 | 0 | Jan 31, 2025 |
| Jan 27, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,172 | $0.00 | $0 | 0 | Jan 31, 2025 |
| Jan 27, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -641 | $0.00 | $0 | 0 | Jan 31, 2025 |
| Jan 27, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,928 | $0.00 | $0 | 52,785 | Jan 31, 2025 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | AKRObuy Akero Therapeutics, Inc. | G. Walmsley Graham director | $8.8M 200,000 shares | +20% | |
| 12Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $448k 10,000 shares | -10% | |
| 30Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $23k 516 shares | -0% | |
| 42Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $30k 676 shares | -1% | |
| 35Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $28k 614 shares | -1% | |
| 40Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $27k 607 shares | -0% | |
| 49Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $78k 1,738 shares | -0% | |
| 45Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.3M 30,000 shares | -4% | |
| 14Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $557k 12,500 shares | -7% | |
| 2Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $48k 1,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.